PP
FDMT icon

PDT Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

PDT Partners’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,097
Closed -$151K – 560
2025
Q4 		$151K Hold
20,097
– – 0.01% 527
2025
Q3 		$175K Hold
20,097
– – 0.01% 552
2025
Q2 		$74.6K Sell
20,097
-34,902
-63% -$123K ﹤0.01% 675
2025
Q1 		$178K Sell
54,999
-5,916
-10% -$27.9K 0.01% 685
2024
Q4 		$339K Buy
+60,915
New +$478K 0.03% 548
2024
Q3 		– Sell
-39,356
Closed -$826K – 755
2024
Q2 		$826K Sell
39,356
-20,768
-35% -$521K 0.08% 372
2024
Q1 		$1.92M Buy
+60,124
New +$1.53M 0.18% 202
2023
Q2 		– Sell
-10,795
Closed -$186K – 601
2023
Q1 		$186K Sell
10,795
-10,007
-48% -$195K 0.03% 505
2022
Q4 		$462K Buy
20,802
+2,083
+11% +$32.2K 0.07% 406
2022
Q3 		$151K Buy
+18,719
New +$170K 0.02% 752

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PDT Partners's FDMT Position: Q1 2026 in Review

PDT Partners sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 20,097 shares — an estimated $151K sold.

PDT Partners first reported a position in FDMT in Q3 2022 and held it in 10 quarters. The position peaked at $1.92M in Q1 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • PDT Partners reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • PDT Partners sold 20,097 4D Molecular Therapeutics shares in Q1 2026, an estimated $151K.
  • PDT Partners first reported a position in 4D Molecular Therapeutics in Q3 2022 and held it in 10 quarters.
  • PDT Partners's 4D Molecular Therapeutics position peaked at $1.92M in Q1 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.